IN8BIO INC (INAB)

US45674E1091 - Common Stock

1.15  -0.04 (-3.36%)

IN8BIO INC

NASDAQ:INAB (9/26/2023, 3:30:02 PM)

1.15

-0.04 (-3.36%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)N/A N/A
Ins Owners7.43%
Inst Owners7.37%
Market Cap36.34M
Shares31.60M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.5
IPO11-12 2020-11-12
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INAB Daily chart

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 26 full-time employees. The company went IPO on 2020-11-12. The company is focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead product candidates are in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation. The company is also focused on patient enrollment in the Company-sponsored Phase 2 clinical trial of INB-400 in which autologous genetically modified gamma-delta T cells will be assessed in newly diagnosed GBM patients. Its DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing GBM and other solid tumor types.

Company Info

IN8BIO INC

Empire State Building, 350 5Th Avenue, Suite 5330

New York City NEW YORK

P: 16466006438.0

CEO: William Ho

Employees: 26

Website: https://www.in8bio.com

INAB News

News Image8 days ago - IN8bio, IncIN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and...

News Image9 days ago - Seeking AlphaIN8bio director Graff Jeremy acquires 2,500 company shares (NASDAQ:INAB)

IN8bio (INAB) disclosed in an SEC filing dated Sept 15 that director Graff Jeremy R

News Image21 days ago - IN8bio, IncIN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...

News Imagea month ago - IN8bio, IncIN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...

News Image2 months ago - IN8bio, IncIN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated...

News Image2 months ago - IN8bio, IncIN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility

State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative...

INAB Twits

Here you can normally see the latest stock twits on INAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example